Back

Thryv licenses second SGK1 inhibitor scaffold for brain and heart diseases

Verifying
  • Thryv licensed a second SGK1 inhibitor scaffold from CSIC, UAM and FUAM.
  • 2027 is the target year for nominating the first development candidate from the new series.
  • THRV-1268 is being evaluated in WAVE II for Long QT Syndrome Type 2.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.